THe team that drives the science

Chief Executive Officer

Dr. Martin Schmeing is a world-leading expert in the biochemistry and structure of proteins. Martin trained at McGill, Yale and Cambridge with two Nobel laureates. In addition to leadership at Canadienzyme, Martin is a professor in the Department of Biochemistry, where he publishes in the top journals and wins national awards. Martin is the Canada Research Chair in Macromolecular Machines and the Director of the Centre de recherche en biologie structurale

Chief Scientific Officer

Dr. Don van Meyel is an internationally recognized biomedical scientist with expertise in neurobiology, cellular biology, and enzymatic reactions. Don obtained his PhD in Microbiology and Immunology at the University of Western Ontario, and his postdoctoral training in developmental neuroscience at the Salk Institute. In addition to leadership at Canadienzyme, Don is a professor in the Department of Neurology & Neurosurgery at McGill University, Don is the Director of the Centre for Translational Biology, the arm of fundamental research at the Research Institute of the McGill University Health Centre.

Strategic Advisor

Stuart Kozlick, a 20-year MedTech Executive within the Montréal and Québec ecosystem, has developed and accrued subject matter expertise in medical device development, innovation, research, and commercialization. An engineer and entrepreneur specializing in medical technologies, devices and healthcare systems, Stuart is called upon to lead strategic initiatives to integrate and develop complex medical device systems in the clinical field. He is passionate about early-stage ventures and opportunities that require market analysis, needs assessment, product and business model discovery and definition, corporate strategic positioning and planning, and go-to-market execution. As part of his practice, Stuart works and collaborates with industry developers and innovators, government bodies, healthcare institutions, as well as academic and research institutions, among others. 

Over the course of his career, Stuart has led and launched several research, product development and clinical engineering programs, resulting in commercialized products globally. His dedication remains focused on the ever-growing medical ecosystem and revolves around accelerating both the adoption and accessibility of disruptive medical technology to improve patients' lives. Stuart also serves as Professor of Practice in McGill University’s Faculty of Medicine & Health Sciences, Department of Surgery, and as Faculty Lecturer in the University’s Faculty of Engineering, Departments of Bioengineering and Mechanical Engineering, as well as the Faculty of Management, Dobson Centre for Entrepreneurship.

In 2019, Stuart became the city’s first functioning Medtech Fractional Executive and Executive-In-Residence through a partnership with Fasken Martineau DuMoulin law firm. His passion and ambition helped grow several successful startups in the medical ecosystem to date. Additionally in 2019, Stuart became the CEO of Puzzle Medical Devices Inc., a Montréal-based startup company that specializes in the development of cardiovascular medical devices to treat advanced heart-failure patients. Previously, Stuart was Vice President of Medical Robotics & Corporate Operations at Kinova Robotics Inc., a Montréal-based robotics company that specializes in the robotics industry. Prior to this, he served in several leadership and engineering roles at CAE Healthcare, Medtronic Inc., and the former CryoCath Technologies Inc. Stuart continues to support the growing medtech ecosystem of Montréal and abroad through various board positions and in an Advisory/Mentor capacity for entities such as L’institut TransMedTech, CTS Santé, RTI Inc., Innovate Calgary, and TechStars Montréal AI, to name a few.

Stuart’s experience and expertise span multiple medical specialties and areas of concentration including electro-physiology, structural heart, cardiovascular, endovascular, pulmonary, gastrointestinal, orthopedics and minimally invasive therapeutics.